Associate, Roivant Health at Roivant Sciences

New York, New York, United States

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, BiotechnologyIndustries

Requirements

Candidates should be ambitious, entrepreneurial, and comfortable with ambiguity, driven by a passion for building transformational healthcare businesses. They should embrace calculated risk-taking as essential to achieving meaningful outcomes for patients, and possess a desire for rapid career advancement.

Responsibilities

The Associate will support early-stage ideation by identifying and evaluating potential opportunities, developing and executing structured workplans to assess incubation opportunities, conducting both quantitative and qualitative analyses of markets, competitors, and potential validation pathways. They will also contribute to the full company creation process, from early-stage ideation to execution, and foster an open and collaborative culture within the organization.

Skills

Market Analysis

Competitor Analysis

Quantitative Analysis

Qualitative Analysis

Strategic Planning

Business Ideation

Risk Assessment

Roivant Sciences

Develops biopharmaceuticals and RNA therapeutics

About Roivant Sciences

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates in the biopharmaceutical market, which involves creating drugs from biological sources. Roivant's unique business model combines in-house development with strategic partnerships, allowing it to build a strong pipeline of drug candidates and utilize advanced technologies to meet medical needs. A key subsidiary, Genevant, specializes in RNA therapeutics, employing proprietary delivery platforms for mRNA, RNAi, and gene editing to treat specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

New York City, New YorkHeadquarters

2014Year Founded

$1,750.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Risks

Integration challenges from Dermavant acquisition may disrupt operations and delay development.

Regulatory hurdles in Pulmovant collaboration with Bayer could impede progress.

Failure of lupus drug brepocitinib may lead to financial losses and investor concerns.

Differentiation

Roivant Sciences focuses on late-stage drug candidates, reducing development time and cost.

The company builds Vants, nimble biotech firms, to enhance drug development efficiency.

Roivant leverages RNA therapeutics, including mRNA and RNAi, for innovative treatments.

Upsides

Roivant's acquisition of Dermavant expands its dermatology portfolio and therapeutic areas.

Strategic partnerships with Bayer and Roche accelerate drug development and market entry.

Increased investment from financial institutions highlights confidence in Roivant's growth potential.

Land your dream remote job 3x faster with AI

Try Jobo Free